2013 Annual Report - Amazon S3 · of an important initiative that aims to ensure that ASH’s...

American Society of Hematology

2013 Annual ReportS u p p o r t i n g o u r C o m m u n i t i e S

The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and treatments of blood disorders. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.

Presidents’ Letter 1

Annual Meeting 2

Honorific & Annual Meeting Awards 4

Blood Journal 8

Career-Development & Training Awards 10

Advocacy 14

Global Programs & Small Meetings 16

Practice & Quality 20

Education & Training 22

Financial Picture 24

Contributions to ASH 25

Member Benefits 32

Presidents’ Letter

We are proud to share this annual report that celebrates the growth and accomplishments of ASH in 2013. As expressed on the following pages, 2013 was a year of continued innovation and expansion for the Society, specifically for its annual meeting, journal, and programming for hematologists in all stages of their careers. 2013 also represented a year of continued ASH leadership in protecting federal funding for hematology research despite extreme economic uncertainty, with the Society awarding its first Bridge Grants and maintaining a strong presence on Capitol Hill.

In addition to these significant successes, 2013 also marked the beginning of an important initiative that aims to ensure that ASH’s myriad sub-specialty communities continue to thrive. The ASH Communities Project began with a survey of members distributed to learn more about the various communities with which members identify themselves. With survey results as a guide, the Society’s Executive Committee began a more in-depth examination of several specific disease- or physiology-focused communities and created several task forces to spearhead efforts to improve Society programming to further engage these groups.

You may have noticed one result of ASH’s new Communities Project at the 2013 ASH Annual Meeting, which was better geographic coordination of sessions on similar topics, providing the feel of a “meeting within the meeting” for the various scientific sub-communities as they moved between simultaneous abstract sessions. The 2013 ASH Annual Meeting also marked the debut of multiple seating areas, coined “Hematology MeetUps,” placed throughout the Ernest N. Morial Convention Center in New Orleans to enable attendees to meet one another for informal, impromptu conversations and small meetings. We look forward to the continued growth of this effort in 2014, not only at the annual meeting, but in many of the Society’s activities.

We invite you to read more about how ASH supported its various member communities throughout the year – from new content in Blood and scientific community-focused features of the annual meeting to the expansion of quality programming and new resources for the practice community. As a member of ASH, you play a critical role in helping advance our broader hematology community toward the ultimate goal of conquering blood diseases worldwide.

12013 Annual Report

Janis L. Abkowitz, MD2013 President

Linda J. Burns, MD2014 President

2013 ASH Executive Committee2013 Officers:

PresidentJanis L. Abkowitz, MD

President-ElectLinda J. Burns, MD

Vice PresidentDavid A. Williams, MD

SecretaryStephanie J. Lee, MD, MPH

TreasurerRichard A. Larson, MD

Councillors:

Kenneth C. Anderson, MD

Michael A. Caligiuri, MD

Joseph M. Connors, MD

Jonathan D. Licht, MD

Margaret A. Shipp, MD

Marilyn J. Telen, MD

Alexis A. Thompson, MD, MPH

John C. Winkelmann, MD

Annual Meeting

Annual MeetingSHARING BREAKTHROUGHS AND CELEBRATING COMMUNITIES

The 55th ASH Annual Meeting in New Orleans united

more than 22,000 attendees of diverse backgrounds

and expertise from around the world to celebrate the

latest research and clinical advances in hematology. From

abstract and Scientific Program presentations showcasing

breakthroughs in areas ranging from engineered cell

therapies to transplantation, to Education Program sessions

focusing on the latest clinical advances, the meeting provided

attendees countless opportunities to advance their research,

improve their practice, and connect with colleagues.

Finding Your Community at ASH 2013“See you at ASH!” It’s a common expression exchanged by hematologists

throughout the year. While short, it speaks volumes

about the ASH annual meeting and how it represents more

than just a scientific meeting but also a precious opportunity to reunite with former classmates, colleagues, and friends. Hematologists from all over the world make plans to see

one another at the ASH annual meeting; however, sometimes the

meeting’s size and packed schedules make this a challenge.

Understanding the unique opportunity to maximize small, community interactions at such a large meeting, ASH set out to give the 55th ASH Annual Meeting in New Orleans a more intimate feel. Perhaps the most visible feature of the 2013 meeting encouraging attendee connection and networking was the establishment of

“Hematology MeetUp” areas throughout the convention center. For the first time the Society provided these areas – designated on the convention center map and advertised with large signs – for attendees to find each other and set up smaller gatherings throughout the meeting. ASH also made every effort to schedule similar sessions close together geographically to ensure that attendees with similar research and practice interests would have plenty of interaction with like-minded colleagues.

In addition to facilitating small, informal meetings, ASH understands that different groups have different needs at the annual meeting and has taken strides to meet them. For example, the myeloid biology community has traditionally held a workshop during the annual meeting to address the most pressing questions in the field; this session is now an official component of the ASH annual meeting.

This focus on small group experiences at the ASH annual meeting will continue to evolve as ASH strategizes about how to make an incredibly popular meeting feel a little smaller and to make “See you at ASH!” a reality for all attendees.

2 American Society of Hematology

Nearly 4,650 abstracts representing the latest advances in basic, clinical, and translational research in both malignant and non-malignant hematology were presented by attendees from 54 countries.

The Plenary Scientific Session provided attendees with exciting updates on the very latest break-throughs in the field, including the uncovering of the germinal center of B-cell lymphoma, promising results of a new targeted therapy for chronic lymphocytic leukemia, and trial results suggesting that combination therapy might become a new standard of care for patients with newly diagnosed multiple myeloma.

The breakthrough science presented at the 2013 ASH Annual Meeting garnered international attention, with news coverage by ABC News, CNN, TIME, and National Public Radio, as well as prominent newswire services such as the Associated Press, Reuters, and Bloomberg.

32013 Annual Report

BY THE NUMBERS: 2013 ASH ANNUAL MEETINGDecember 7-10, 2013 Ernest N. Morial Convention Center New Orleans, Louisiana

22,346 attendees

Attendees from 112 countries

6,028 abstract submissions

936 oral abstract presentations

3,714 poster presentations

Abstract submissions from 64 countries

2013 Program Co-ChairsEducation ProgramWendy Stock, MDJohn Tisdale, MD

Scientific ProgramJosé Lopez, MDKevin Shannon, MD

Nearly 200 invited speakers covered important updates during the Education and Scientific Programs, providing invaluable information on the latest clinical and scientific advances in key areas of hematology.

The 2013 ASH Annual Meeting marked the debut of ASH News TV, a daily newscast featuring highlights from the meeting broadcast throughout the convention center, in hotel rooms, online, and on shuttle buses. Interviews with ASH leaders and meeting participants gave attendees a better glimpse of all the annual meeting had to offer.

“ ASH’s strengths are our diversity and that we are a single voice for a broad field. However, while ASH continues to provide resources and services for hematologists in all areas, the enormous growth in the size of the annual meeting has made it increasingly more difficult to maintain a sense of community among our various smaller, sometimes distinct and sometimes overlapping, constituencies. ASH’s leadership is committed to ensuring that these communities persist and thrive.”

– 2013 ASH President Janis L. Abkowitz, MD

From the CNN.com story, “Killing Cancer like the Common Cold.”

NBC News’ “Nightly News with Brian Williams.”

ASH News TV presented recaps of each day’s hottest presentations as well as behind-the-scenes features and sneak peeks of upcoming sessions.

Honorific & Annual Meeting Awards

Honorific & Annual Meeting AwardsHONORING LEADERS IN OUR COMMUNITY

A highlight of each ASH annual meeting is the recognition

of outstanding achievements in hematology. The Society’s

highest honors recognize significant contributions to the

field of hematology.

Wallace H. Coulter Award for Lifetime Achievement in Hematology Professor Sir David Weatherall, MD, University of Oxford, Oxford, United Kingdom

Professor Sir David Weatherall, MD, was honored with the 2013 Wallace H. Coulter Award for Lifetime Achievement in Hematology, the Society’s highest honor, for his more than 50-year career in hematology combining seminal discoveries, visionary translational research leadership, and a passion for global health initiatives that have together helped improve clinical care for thousands throughout the developing world. This award, named for the late Wallace Henry Coulter, a prolific inventor and entrepreneur who revolutionized the practice of hematology and laboratory medicine with the invention of the Coulter Counter®, is bestowed on an individual who has demonstrated a lifetime commitment to hematology and who has made outstanding contributions to education, research, and practice.

A true pioneer in the field, Sir David has paved the way for other physicians and scientists in refining the understanding of inherited blood disorders, particularly thalassemias and tropical diseases. His groundbreaking and transformative discovery in 1965 identifying imbalanced globin chain production as the cause of thalassemia was essential to developing improved treatments and designing disease prevention efforts at both the clinical and population levels. In addition to his accomplishments in the laboratory and at the patient bedside, Sir David has also built a successful framework of international clinical and research partnerships and led development efforts to build new treatment and diagnostic centers in developing countries.



Henry M. Stratton MedalNancy Andrews, MD, PhD, Duke University School of Medicine, Durham, NC

Elaine Jaffe, MD, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Nancy Andrews, MD, PhD, and Elaine Jaffe, MD, were awarded the 2013 Henry M. Stratton Medal, named after the late Henry Maurice Stratton, co-founder of Grune and Stratton, the medical publishing house that first published ASH’s journal Blood, for their outstanding accomplishments in the fields of iron homeostasis and erythropoiesis and lymphoma, respectively.

Dr. Andrews, the Basic Research Award recipient, is a model physician-scientist and a recognized leader in the study of erythropoiesis and the molecular biology of iron metabolism. She is the first appointed female dean of Duke’s School of Medicine and the only woman to lead one of the nation’s top 10 medical schools. Dr. Jaffe, the Clinical/Translational Research Award recipient, is regarded by her peers as one of the most pre-eminent hematopathologists of her generation. She is most widely known for her many notable breakthroughs regarding the pathophysiology and prognosis of malignant lymphomas and intriguing work on the interrelationship between Hodgkin lymphoma and B-cell lymphomas.

William Dameshek PrizeAndrew S. Weyrich, PhD, The University of Utah, Salt Lake City, UT

Andrew S. Weyrich, PhD, was awarded the 2013 Dameshek Prize for his seminal research investigating the evolving role of platelets in inflammation and thrombosis. This award, named for the late William Dameshek, MD, a renowned hematologist, past president of ASH, and first editor of the Society’s journal, Blood, honors an individual who has made a recent outstanding contribution to the field of hematology. Dr. Weyrich’s recent research accomplishments, which include his successful identification of the mRNA splicing and translational mechanisms that allow platelets to respond to environmental changes, have placed him at the forefront of redefining platelet function.

52013 Annual Report


E. Donnall Thomas Lecture and PrizeKatherine A. High, MD, Howard Hughes Medical Institute and The Children’s Hospital of Philadelphia, Philadelphia, PA

Katherine A. High, MD, was awarded the 2013 E. Donnall Thomas Lecture and Prize for her unparalleled work in identifying the molecular

basis of hemophilia and developing novel genetic therapies to treat the disorder. This lectureship and prize, named after the late Nobel

Prize Laureate and past Society president E. Donnall Thomas, MD, recognizes pioneering research achievements in hematology. As a leading

expert in gene therapy of hemophilia, Dr. High has dedicated her career to bringing this novel and complex concept to fruition. Her more than 15 years of

investigation surrounding gene therapy for hemophilia has culminated in successful clinical studies utilizing adeno-associated virus vector-mediated gene transfer for the

treatment of hemophilia B.


Ernest Beutler Lecture and Prize Kenneth Kaushansky, MD, Stony Brook University, Stony Brook, NY

David J. Kuter, MD, DPhil, Massachusetts General Hospital Cancer Center, Boston, MA

Kenneth Kaushansky, MD, and David J. Kuter, MD, DPhil, were awarded the 2013 Ernest Beutler Lecture and Prize for their significant advances in the discovery of thrombopoietin (TPO), the platelet growth factor that regulates platelet production. This award and lectureship, named for the late Ernest Beutler, MD, a past president of ASH, is presented to two individuals to recognize major translational advances related to a single topic.

Dr. Kaushansky, who served as ASH president in 2008, was honored for his seminal research advances in hematopoiesis, including the discovery of TPO, the cytokine that helps to expand hematopoietic stem cells and promotes the expansion and maturation of megakaryocytes. Dr. Kuter was recognized for his critical contributions to hematology, including his work to translate the understanding of cytokine signaling in megakaryopoiesis into clinical practice.


Ham-Wasserman LectureClara Camaschella, MD, Vita-Salute University and San Raffaele Scientific Institute, Milan

Clara Camaschella, MD, presented the 2013 Ham-Wasserman Lecture, “Iron and Hepcidin: A Story of Recycling and Balance,” which discussed iron homeostasis and its importance to the field of hematology. In her lecture, Dr. Camaschella explained the current approaches to manipulating the hepcidin axis and provided a critical assessment of the potential clinical applications. This lecture, created to honor the late renowned hematologists Thomas Hale Ham, MD, and Louis R. Wasserman, MD, is traditionally given by an individual from outside the United States who has contributed significantly to an area of hematology.

Mentor AwardJohn Adamson, MD, University of California – San Diego, San Diego, CA

Stanley Schrier, MD, Stanford University School of Medicine, Stanford, CA

John Adamson, MD, and Stanley Schrier, MD, were presented with the 2013 Mentor Award to honor their excellence in mentoring trainees and colleagues. Dr. Adamson, the recipient of the 2013 Basic Science Mentor Award, and Dr. Schrier, recipient of the 2013 Clinical Investigation Mentor Award, were honored for the significant, positive impact they have had on trainees’ careers. Through their trainees, they have advanced research and patient care in the field of hematology.

Dr. Adamson, who served as ASH president in 1996, has been particularly exceptional at

forging bonds among early-career investigators with similar interests and has consistently

taught and lived by the model that early-career hematologists need protected time to develop their scientific skills. Dr. Schrier, who served as ASH president in 2004, has dedicated tremendous amounts of energy to advancing the clinical and research skills of his colleagues and trainees not only at Stanford, but around the world, inspiring several generations of his trainees to become international experts

in hematologic malignancies.

72013 Annual Report

Blood Journal

Blood JournalSHOWCASING BREAKTHROUGHS ACROSS HEMATOLOGY

2013 was a year of innovation, progress, and transition for the Society’s

flagship journal, Blood, the most cited peer-reviewed publication in the

field. In addition to publishing manuscripts detailing the most exciting basic,

clinical, and translational hematology research breakthroughs across its

print and online editions, in 2013 Blood launched several new article types,

started publication of a “Review Series in Hematology,” and offered an

improved article format and fresh cover design.

New BloodIn January 2013 the Society welcomed Bob Lӧwenberg, MD, PhD, Professor of Hematology at Erasmus University Medical School, as new Blood editor-in-chief and Nancy Berliner, MD, Chief of Hematology at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, as the journal’s first-ever deputy editor.

In their first year of service to the journal, Drs. Lӧwenberg and Berliner implemented several new features, including the addition of “key points” to summarize the most important points of each manuscript, the launch of several new article types such as “Blood Spotlight” and “Blood Forum,” and several

“Review Series in Hematology” designed to appeal to both scientists and clinicians. Blood’s new leaders also oversaw the development and launch of several new enhancements to Blood Online, including “Blood Hubs,” centralized resources on the Blood website that aggregate all journal content relating to a specific area in hematology.


How I Treat – A Compendium for the Practicing HematologistIn 2013 ASH published a new compendium featuring 33 “How I Treat” articles published in Blood that have been reviewed and updated to reflect the most recent scientific and clinically relevant information discovered since the articles were first published. The volume focuses on areas of hematology where there have been significant changes in understanding of the biology of diseases and/or where clinical developments have significantly evolved.

Countries with the most accepted manuscripts in Blood in 2013:

Country Number of Acceptances

United States 728Germany 103United Kingdom 100Italy 74France 67Canada 62Netherlands 55Australia 38Japan 35Sweden 24

Blood Journal

Best of BloodTo celebrate the outstanding achievements in both hematology and in Blood in 2013, Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD, have selected the following manuscripts as the most outstanding in the following categories.

Hematopoiesis and Stem Cells“In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells,” Amabile et al.

Immunobiology“Loss-of-function of the protein kinase C delta (PKCδ) causes a B cell lymphoproliferative syndrome in humans,” Kuehn et al.

Lymphoid Neoplasia“Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia,” Rajala et al.

Myeloid Neoplasia“Clinical and biological implications of driver mutations in myelodysplastic syndromes,” Papaemmanuil et al.

“European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013,” Baccarani et al.

Myeloid Neoplasia/Clinical Trials and Observations“Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis,” Cervantes et al.

Myeloid Neoplasia/Phagocytes/Granulocytes/Myelopoiesis“Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation,” Haroche et al.

Hematopoiesis and Stem Cells“RNAi screen identifies Jarid1b as a major regulator of mouse HSC activity,” Cellot et al.

Sickle Cell Disease/Red Cells, Iron, and Erythropoiesis“Mast cell activation contributes to sickle cell pathobiology and pain in mice,” Vincent et al.

Thrombosis and Hemostasis“Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis,” Lechtenberg et al.

“Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial,” Mannucci et al.

Transplantation/Gene Therapy“Multicenter study of banked third-party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation,” Leen et al. “Toward eliminating HLA class I expression to generate universal cells from allogeneic donors,” Torikai et al.

92013 Annual Report

Blood Forum Article Draws Attention to Cost-of-Cancer DebateOpinion piece by more than 100 leukemia experts makes headlines around the globeIn early 2013 a group of more than 100 of the world’s foremost experts in chronic myeloid leukemia (CML) submitted an article to Blood protesting the high costs of CML drugs. The piece, published in April as a Blood Forum article (a new article type intended to present opinions on controversial topics in the field), thrust the long-debated issue of the cost of cancer care into the spotlight, igniting a passionate dialogue that swept the international community. The authors pointed out that, while revolutionary treatments for CML have transformed it from a once uniformly fatal disease to one that can be managed with daily oral therapy, the steadily increasing costs of these treatments are standing in the way of patients’ survival. This Blood Forum article continues to be one of the most discussed in the history of the journal and has been featured in nearly 400 news stories in outlets such as The New York Times, CBS Evening News, The Washington Post, and CNN.

“ As physicians, we follow the Hippocratic Oath of ‘Primum non nocere,’ first (or above all) do no harm. We believe the unsustainable drug prices in CML and cancer may be causing harm to patients. Advocating for lower drug prices is a necessity to save the lives of patients who cannot afford them.”

– Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22): 4439-4442.

To read descriptions and access links to each manuscript, visit www.hematology.org/bestofblood2013.

Career-Development & Training Awards

Career-Development & Training AwardsINVESTING IN THE FUTURE OF HEMATOLOGY

ASH is committed to supporting the next generation of

hematology leaders through its career-development awards

and programs, which provided nearly $5 million in educational

grants to emerging investigators in 2013. ASH also committed

an additional $3 million in bridge funding to support

investigators affected by NIH funding cuts.

ASH Awards First Bridge GrantsPediatric hematologist/oncologist Christopher Porter, MD, one of several Bridge Grant success stories

In summer 2012, ASH member Christopher Porter, MD, knew the future of his research on novel treatments for pediatric leukemia stood in jeopardy. Like many other ASH members, Dr. Porter, a pediatric hematologist/oncologist at Children’s Hospital Colorado in Aurora, Colorado, had reason to worry: a major source of funding for his lab, the National Institutes of Health (NIH), stood to weather drastic budget cuts as part of an ongoing budget battle in Washington.

In his Aurora lab, Dr. Porter and colleagues use cutting-edge tools to examine the entire genome and identify genes that, when inhibited, sensitize leukemia cells to conventional chemotherapy. While Dr. Porter and colleagues were confident that this work could one day revolutionize childhood leukemia treatment, the team’s application for a research project grant (R01) from the National Cancer Institute at NIH was ultimately denied, despite having scored well.

“The work we do is very exciting and challenging, but it’s also very expensive,” said Dr. Porter. “My lab had been able to report exciting preliminary data with startup funding from my institution, but the data needed thorough preclinical evaluation before

we could start talking about clinical trials, and our funds were starting to wane.”

Dr. Porter was not alone in his plight. In fact, according to NIH estimates, the combination of long-term flat funding and across-the-board federal budget cuts (known as “sequestration”) prevented NIH from funding approximately 700 competitive research project grants in 2013. In need of supplemental funding, Dr. Porter applied for and was among the first 29 ASH members to receive an ASH Bridge Grant in 2013, a new award designed to help support promising ASH member scientists amidst a challenging NIH funding climate.

Established in 2012, the ASH Bridge Grant program is intended to help “bridge” talented ASH member investigators in basic, clinical, and translational research whose NIH R01 research grant applications scored highly but were not funded. The program, which will support approximately $9 million in hematology research, is intended to support recipients as they gather additional data in order to strengthen the resubmission of their NIH grant applications.

ASH Bridge Grant-funded projects span the breadth of hematology, ranging from the pediatric leukemia work in Dr. Porter’s lab to the exploration


Bridge Grant recipient Christopher Porter, MD.

ASH Recognized for Award ProgramThe ASH Bridge Grant program was recently recognized by the American Society of Association Executives as a model in the association community, earning a 2013 Summit Award, the organization’s highest honor, for excellence in working to create a stronger America and world.

Career-Development & Training Awards 112013 Annual Report

ASH Abstract Achievement AwardsThis award category provides monetary support to select trainees with high-achieving abstracts accepted for the ASH annual meeting and includes the Outstanding Abstract Achievement Awards, Minority Graduate Student Abstract Achievement Award, and the Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis.

ASH-AMFDP AwardDesigned to increase the number of underrepresented minority scholars in the field of hematology with academic and research appointments, this award is presented in partnership with the Robert Wood Johnson Foundation’s Amos Minority Faculty Development Program (AMFDP).

ASH Bridge GrantsThis new award program is designed to provide ASH members who applied for an NIH R01 grant or equivalent but were denied funding with critical interim support to help them continue their critical research amid severe NIH funding reductions.

ASH HONORS AwardNewly revised and renamed for 2013, the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award (formerly known as the ASH Trainee Research Award) aims to encourage North American medical students and residents who have a demonstrated interest in conducting hematology research but who have not yet entered a hematology-related training program to pursue a research career in the field.

ASH Executive Director Martha Liggett, Esq., and 2013 ASH President Janis L. Abkowitz, MD, accept a 2013 Summit

Award for the Society’s Bridge Grant program

from American Society of Association Executives

President & CEO John H. Graham IV, FASAE, CAE, at an

awards banquet in Washington, DC.

Léon Kautz, PhD, a postdoctoral fellow at UCLA and ASH Scholar, accepts the 2013 Joanne Levy, MD, Memorial Award for Outstanding Achievement.

of how computerized tomography scans may impact the use of chemotherapy for blood cancers to the study of the function of impaired gene expression in a type of congenital anemia.

With support from an ASH Bridge Grant and matching funds from his institution, Dr. Porter was able to continue collecting the data he needed to reapply for an R01. In the summer of 2013 he received the good news that his additional efforts had paid off and his revised R01 application had been funded.

“The ASH Bridge Grant is an excellent way for researchers to maintain productivity at a time when receiving NIH funding is exceedingly difficult,” said Dr. Porter. “The funds from the ASH Bridge Grant allowed my lab to continue to work on this project uninterrupted. I was able to keep people in the lab that I may have had to let go otherwise. In the absence of the program, I’m not sure what would have happened.”

To date, nearly one-third of the ASH members who received Bridge Grant support in 2013 have subsequently received NIH funding. Through the ASH Bridge Grant program, ASH is committing to members like Dr. Porter who have dedicated their careers to hematology research, and to the patients who may one day benefit from their future discoveries.

To learn more about ASH’s Bridge Grant program and to view a list of recipients, visit www.hematology.org/bridgegrants.

To browse a list of ASH Career Development & Training award recipients, including 2013 award recipients, visit www.hematology.org/awardrecipients.

Career-Development & Training Awards

In 2013, ASH awarded nearly $8 million in educational and research grants through the following awards to benefit hematologists at all levels of their careers:Abstract Achievement Awards• Number of Abstract Achievement

Award recipients in 2013: 782

• Amount awarded to each Abstract Achievement Award recipient: $500

• Number of Outstanding Abstract Achievement Award recipients in 2013: 6

• Amount awarded to each Outstanding Abstract Achievement Award recipient: $1,500

• Number of Minority Graduate Student Abstract Achievement Award recipients in 2013: 4

• Amount awarded to each Minority Graduate Student Abstract Achievement Award recipient: $1,500

• Additional amount awarded to recipient of Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis: $6,000

• Total awarded in 2013: $412,000

ASH-AMFDP Award (four-year awards)• Number of recipients in 2013: 1• Amount awarded to recipient: $420,000


ASH Bridge Grants (one-year awards)• Number of recipients in 2013: 29

• Amount awarded to each recipient: $100,000

• Total awarded in 2013: $2,900,000

ASH HONORS Award• Number of recipients in 2013: 30

• 2013 annual stipend awarded: $5,000 per recipient, $150,000 total

• 2013 ASH Annual Meeting travel allowance awarded: $1,000 per recipient, $24,000 total


Clinical Research Training Institute• Number of participants in 2013: 21

• Cost per participant*: $15,830

• Total 2013 program cost: $332,430

Minority Medical Student Award Program • Number of recipients in 2013: 15

• Amount awarded to each recipient: $6,000

• Travel stipend per recipient: $1,000


Research Training Award for Fellows • Number of recipients in 2013: 6• Amount awarded to each

recipient: $50,000


Scholar Awards (two- to three-year awards)• Number of recipients in 2013: 23

• Amount awarded to each fellow recipient: $100,000

• Amount awarded to each junior faculty recipient: $150,000

• Additional amount awarded to recipient of Joanne Levy, MD, Memorial Award for Outstanding Achievement: $3,500

• Total awarded in 2013: $2,850,000

Translational Research Training in Hematology • Number of participants in 2013: 20

• Approximate cost per participant*: $16,538

• Total 2013 program cost: $330,760


Clinical Research Training InstituteASH’s Clinical Research Training Institute prepares hematologists for careers in patient-oriented clinical research through an intensive year-long education and mentoring program.

Minority Medical Student Award ProgramThrough this program, minority students from the United States and Canada in their early medical school years are provided with monetary support to conduct a hematology research project under the guidance of an ASH member.

Physician-Scientist Career Development AwardIntroduced in 2013, the Society’s Physician-Scientist Career Development Award provides support for medical students interested in the field to pursue high-impact basic, clinical, or translational hematology research under the mentorship of an ASH member.

Total awarded in 2013: $7,824,190

* Value of award as opposed to actual check amount

Career-Development & Training Awards 132013 Annual Report

Research Training Award for FellowsThis award provides funding to fellows in hematology, hematology/oncology, or hematology-related training programs who need protected time to perform research during fellowship training.

Scholar Awards ASH Scholar Awards provide talented researchers with critical financial support required during the transitional period between completion of training and achievement of status as an independent investigator. In addition, each year the current ASH Scholar with the highest scoring abstract at the ASH annual meeting is honored with the Joanne Levy, MD, Memorial Award for Outstanding Achievement.

Translational Research Training in HematologyOffered in conjunction with the European Hematology Association (EHA), this CME-accredited program provides a select group of participants with personalized training in translational hematology research and unique opportunities for networking and mentoring.

The ASH Foundation: Moving Hematology Forward Through Research, Education, and Quality Care

The ASH Foundation was launched in 2012 to build on the work of ASH by harnessing the generosity of donors to increase the number of awards provided through established programs and to allow the development of innovative programs that address critical issues facing researchers and clinicians.

Through contributions from ASH members and supporters, the ASH Foundation supports a spectrum of new or enhanced ASH programming in three broad categories, including research, career development, and quality care and education. This includes initiatives such as

ASH’s Bridge Grants, Scholar Awards, Global Programs, Clinical Research Training Institute, and Minority Recruitment Initiative.

Because ASH covers all management and administrative costs for programs supported by the Foundation, 100 percent of donations are allocated toward direct program expenses.

Visit www.hematology.org/foundation to learn more and make a donation today.

More than 400 annual meeting attendees participated in the first ASH Foundation 3K Run/Walk held in New Orleans’ historic French Quarter.

Advocacy

AdvocacyREPRESENTING THE HEMATOLOGY COMMUNITY IN WASHINGTON

During 2013, ASH further advanced its advocacy on behalf of the

hematology community, focusing on several issues important to

hematology researchers, clinicians, and their patients. ASH’s efforts

were successful on several fronts, helping to advance regulations to

address drug shortages and also to focus congressional attention on

reforming physician payment under Medicare. The Society also remained

one of the most visible advocates for federal support of biomedical

research and protecting funding for the National Institutes of Health

(NIH) in 2013, with ASH members writing thousands of letters

to Congress and conducting hundreds of visits to Capitol Hill.

ASH Rallies for Medical Research On April 8, 2013, ASH joined several thousand researchers, clinicians, and patients at the “Rally for Medical Research” in Washington, DC, to publicly express support for NIH and raise awareness of the importance of sustained investment in the agency to fund lifesaving biomedical research.

ASH supported the rally as the sole Platinum Sponsor and continued the momentum by supporting a follow-up event, the “Rally for Medical Research Congressional Reception and Hill Day,” in September. ASH’s support of these events was one of many components of the Society’s “Fight 4 Hematology” campaign to address devastating NIH budget cuts, which included the establishment of the ASH Bridge Grant program, the ASH Foundation, and increased advocacy and communications about this critical issue.


ASH Bridge Grant recipients Bihui Hilda Ye, PhD; Suzanne Lentzsch, MD, PhD; and Michele Redell, MD, PhD; at the “Rally for Medical Research” in Washington, DC.

“The future of health care will be impacted by cuts to biomedical research funding today. Declining federal research means we will not be prepared for the next epidemic or positioned to put some of the promising new genomic research into action at the bedside. ASH is standing up for the future of the field by working with Congress to ensure our representatives understand what’s at stake.” – Alan Lichtin, MD, Chair, ASH Committee on Government Affairs

Advocacy 152013 Annual Report

ASH Advocates for NIH FundingWhether on the steps of the U.S. Capitol or in their offices and homes, ASH members took action in 2013 to urge Congress to protect NIH from additional funding cuts threatening U.S. biomedical research. Hundreds of congressional visits were made by ASH members and more than 1,100 members of the ASH Grassroots Network sent more than 4,000 messages to Congress focusing on the value of NIH and the need to develop a balanced approach to deficit reduction that did not involve cuts to NIH or other critical federal programs.

Physician Payment ReformIn 2013 ASH was a passionate advocate for fair Medicare physician payment, urging Congress to repeal the flawed Sustainable Growth Rate (SGR) and replace it with a predictable, stable, and quality-based payment system. Throughout the year, ASH submitted comment letters to Congress in response to legislative proposals and also developed an online letter-writing campaign for the Society’s members. ASH Committee on Practice members and Advocacy Leadership Institute participants also echoed the Society’s key message during several days of visits to Capitol Hill.

Drug ShortagesWhile shortages of hematologic drugs have plagued hematologists and their patients over the past several years, 2013 brought encouraging progress, thanks in part to ASH advocacy on the issue. On October 31, 2013, the U.S. Food and Drug Administration released a strategic plan to combat drug shortages and a proposed rule requiring manufacturers to report discontinuance or disruption in drug production. Of particular significance to the Society was the inclusion of biologic products in the agency’s strategic plan and the early notification requirements that were based on ASH guidance.

Oral ParityWhile oral and other patient-administered forms of chemotherapy have become more prevalent and represent the standard of care for many cancers, they are covered differently than physician-administered drugs, leaving many patients responsible for high monthly co-payments. In 2013 ASH members visited Capitol Hill to advocate for oral drug coverage parity legislation that would greatly reduce the financial burden faced by patients with cancer. Both the U.S. Senate and House of Representatives introduced legislation in 2013 to address oral anticancer drug parity legislation, and ASH will continue its strong support of this issue.

Advocacy Leadership InstituteIn October 2013, 25 ASH members eager to gain a deeper understanding of policy issues affecting hematology traveled to ASH headquarters in Washington, DC, to participate in the Society’s third Advocacy Leadership Institute (ALI). The event, held October 22-23, 2013, and hosted by ASH Committee on Government Affairs Chair Alan Lichtin, MD, provided participants with a unique opportunity to learn more about government affairs, gain a better understanding of policy making and Congress, and become more engaged in ASH’s advocacy efforts and the Society as a whole.

Following a comprehensive training complete with sessions on the legislative process, health policy, advocacy strategies, and an overview of ASH’s programs, ASH ALI participants

took to Capitol Hill, completing nearly 40 visits to their congressional delegations to discuss issues critical to hematology research and practice. Participants had two advocacy priorities during visits with their Members of Congress: the first was to demonstrate the significance of federal research funding to their states, congressional districts, institutions, and individual research projects and the second was to urge Congress to repeal the Sustainable Growth Rate formula and reform Medicare reimbursement for physician services.

2013 Advocacy Highlights

Global Programs & Small Meetings

Global Programs & Small MeetingsEXPANDING THE ASH COMMUNITY

ASH continued to expand its international footprint in 2013 through its

global programs and small meetings that promote cross-cultural educational

opportunities and bring the latest scientific and practice updates to the

greater, worldwide hematology community.


ASH Maintains Healthy Partnership with Health Volunteers OverseasSociety launches Tanzania site; achieves critical milestones in Cambodia in 2013 ASH partners with Health Volunteers Overseas (HVO), a nonprofit organization dedicated to improving global health through education, to bring consultation and training to hospitals that manage hematology patients in the developing world. The ASH-HVO collaboration has led to the development of volunteer sites in Cambodia, Peru, and Uganda; in 2013, the partnership launched a new site at Muhimbili National Hospital in Dar-es-Salaam, Tanzania.

Tanzania faces significant challenges as it has the world’s fourth-highest prevalence of sickle cell anemia, as well as high populations of patients with iron deficiency anemia, chronic disease (especially HIV) anemia, aplastic anemia, leukemia (CML, ALL), and various types of bleeding disorders. Through ASH’s partnership with HVO, the site in Tanzania is addressing, among other issues, a significant population of patients with sickle cell disease and leukemia. The volunteer program is training on-site personnel in laboratory diagnostics, chemotherapy administration, and a wide range of other patient management strategies for hematologic disorders. Muhimbili National Hospital and the affiliated Muhimbili University of Health and Allied Sciences provide a special opportunity for ASH members to volunteer and to increase awareness of the indisputable need for improved patient care in countries around the world.

In November 2013, the ASH-HVO volunteer site at Angkor Children’s Hospital in Siem Reap, Cambodia, experienced a very important milestone when volunteers administered the site’s first round of chemotherapy to a pediatric leukemia patient. Thanks to collaborative efforts with ASH-HVO program volunteers and St. Jude Children’s Research Hospital, who have supported and amplified the volunteer program at this site, Angkor Children’s Hospital has been able to gradually develop a malignant hematology program with the capability of chemotherapy administration.

Global Programs & Small Meetings 172013 Annual Report

Visitor Training Program ASH’s Visitor Training Program (VTP) provides opportunities for health-care professionals from developing countries to train for up to 12 weeks in a specific area of hematology that addresses priority issues at the trainee’s home institution. Training is carried out in a clinic or laboratory under the mentorship of an ASH member, and there are no geographic barriers. The ultimate goal of the ASH VTP is to build hematology capacity in developing countries to improve both research and patient care globally.

CRTI in Latin AmericaASH launched its Clinical Research Training Institute in Latin America (CRTI-LA) on April 24, 2013, in Santiago, Chile. Held prior to the Highlights of ASH meeting in Latin America, this program brought together 14 early-career, mid-level, and senior hematology faculty engaged in clinical research and training from Argentina, Brazil, Chile, Colombia, Peru, Uruguay, and Venezuela to participate in four didactic sessions and small-group breakout sessions. During the first-ever CRTI-LA, participants gained more familiarity with clinical trial design and execution and developed greater insight into the importance of mentoring future early-career trainees in clinical research.

“ My successful completion of the ASH Visitor Training Program at Howard University Hospital in Washington, DC, propelled the organization of an in-lab training program on peripheral blood cell identification and manual differential count at my home institution in Ghana.”

– VTP Participant John Kuadzi, BSc, Ghana

Global Programs & Small Meetings18 American Society of Hematology

Highlights of ASH in North AmericaIn January and February 2013, ASH hosted six official Highlights of ASH in North America meetings in Dallas, Miami, New York, San Diego, San Francisco, and Toronto. The meetings, which provided highlights on the latest basic and clinical research findings from the 2012 ASH Annual Meeting, were held in partnership with the Texas Society of Clinical Oncology (Dallas), the Florida Society of Clinical Oncology (Miami), the New York State Society of Medical Oncologists and Hematologists and the Medical Oncology Society of New Jersey (New York), the Medical Oncology Society of Southern California (San Diego), the Association of Northern California Oncologists (San Francisco), and the Canadian Hematology Society (Toronto).

Highlights of ASH® From January through May, ASH brought the most exciting science from the 54th ASH Annual Meeting to hematologists in North America, Latin America, and Asia for the only official “Highlights” meetings sponsored by the Society. The eight 2013 Highlights of ASH meetings featured leading hematology experts who presented unbiased analysis of the 2012 annual meeting abstracts and sessions on evolving therapies, the latest treatment options, and their clinical applications.

Dallas Miami New York San Diego San Francisco Toronto

Global Programs & Small Meetings 192013 Annual Report

Highlights of ASH in Latin AmericaOn April 25-26, 2013, ASH conducted its fifth Highlights of ASH meeting in Latin America in Santiago, Chile, in partnership with the Sociedad Chilena de Hematología. The meeting attracted 762 attendees from 18 countries.

Highlights of ASH in AsiaASH hosted its second Highlights of ASH in Asia meeting in Shanghai, China, March 22-24, 2013. The meeting, which was co-sponsored by the Chinese Society of Hematology, attracted 1,200 attendees, including more than 300 from other Asia-Pacific countries. The 2013 Highlights of ASH in Asia meeting also featured a poster session which included 38 poster presentations by hematologists from the region.

Santiago

Los Angeles

Shanghai

State-of-the-Art SymposiaIn 2013, ASH held its clinically focused, CME-accredited State-of-the-Art Symposia in Chicago and Los Angeles. These small meetings featured case-based presentations by renowned speakers, interactive discussions, and a special networking “lunch with the experts,” with content focused on recent advances in hematologic malignancies and myelodysplastic syndromes.

Consultative Hematology CourseASH’s Consultative Hematology Course, a refresher course on commonly encountered clinical problems requiring the expertise of a hematologist, was offered in conjunction with the 2013 ASH State-of-the-Art Symposia meeting in Chicago and at the 2013 ASH Annual Meeting in New Orleans. The course covered topics ranging from hemolytic anemias and acquired coagulation disorders to clinical conundrums in transfusion medicine, thrombosis in cancer, and new oral anticoagulants.

Chicago

Practice & Quality

Practice & QualityIMPROVING THE QUALITY OF OUR PRACTICE

The landscape of quality improvement in health care is constantly changing.

With quality benchmarks now tied to physician reimbursement, Maintenance

of Certification programs, and tenets of the Affordable Care Act, defining and

measuring quality has taken on even greater significance. In response to member

requests for additional support in this area, ASH is developing a

robust Quality Initiative to address current needs and build

new ASH quality-improvement programs.


ASH Releases List of Commonly Used Tests and Treatments to Question as Part of Choosing Wisely® CampaignIn December 2013 ASH released an evidence-based list of five hematology tests, treatments, and procedures to question – ranging

from thrombophilia testing in patients with acute venous thromboembolism to surveillance computed tomography scans for asymptomatic lymphoma patients in remission – in an effort to prompt conversations between hematologists and their patients about the necessity and potential harm of certain practices. The release of ASH’s list was part of the Society’s involvement in Choosing Wisely, an initiative of the American Board of Internal Medicine Foundation designed to support and engage physicians in identifying common tests, treatments, and procedures that are not always necessary. ASH’s Choosing Wisely list was released in conjunction with the publication of a manuscript in Blood and Hematology 2013 (the ASH Education Program), detailing list-development methodology and was also highlighted in a special session as part of the 2013 ASH Annual Meeting Education Program.

ASH Releases PQRSProIn 2013, ASH released the new ASH PQRSPro Registry System, a tool designed to help ASH members comply with reporting requirements in the Centers for Medicare and Medicaid Services (CMS) Physician Quality Reporting System (PQRS). The PQRS provides incentive payments to eligible physicians and other practitioners who satisfactorily report data on quality measures for covered services furnished during a reporting period. The ASH PQRSPro system helps members by validating that their reporting is incentive-eligible so they can avoid impending payment adjustments.

To access a webinar on the ASH PQRSPro system visit www.hematology.org/PQRS.

ASH Practice Partnership GrowsThe ASH Practice Partnership (APP), the Society’s network for practice-based hematologists, continued to expand in 2013, adding new members and holding its third annual luncheon during the 2013 ASH Annual Meeting. The 2013 ASH Annual Meeting APP luncheon focused on implications of the Patient Protection and Affordable Care Act (PPACA) for hematologists. Members discussed several important considerations surrounding the law, including participating in exchanges, valuing payment rates, and determining eligibility. In addition, members were encouraged to take ownership of how the law is applied to hematologists and get involved in their state or region’s PPACA implementation.

Learn more about the APP at www.hematology.org/APP.

Consult-a-Colleague Program ExpandsIn 2013, ASH added new consultants on hemoglobinopathies and thrombocytopenias to its Consult-a-Colleague program, a service for ASH members that allows them to seek consultations from other ASH members on tough clinical cases. With the addition of these two additional topic areas in 2013, ASH’s Consult-a-Colleague service can now connect ASH members to help solve clinical issues in 11 disease categories.

Learn more about Consult a Colleague by visiting www.hematology.org/consult.

ASH Releases Pocket GuidesIn 2013, ASH released a new pocket guide on Thrombocytopenia in Pregnancy and an updated pocket guide on Heparin-Induced Thrombocytopenia as part of its popular collection of Quick-Reference Guides. The pocket guides distill key information on select diseases from clinical practice guidelines and other sources to create an easy-to-reference resource for the busy clinician. The pocket guides are also available via a free and convenient mobile app.

For more information visit www.hematology.org/pocketguides.

Practice & Quality 212013 Annual Report

ASH Conducts Survey of Practice-Based HematologistsIn 2013, ASH conducted a survey of the Society’s practice-based members to further understand the demographics and needs of this subset of the Society’s members. The survey yielded a high response rate and results will continue to assist ASH in strengthening the Society’s current programs for clinicians, identifying programming and information gaps, and developing new practice-related programs and initiatives to meet the most pressing needs of its members.

Education & Training

Education & TrainingEXPANDING EDUCATION AND TRAINING FOR THE HEMATOLOGY COMMUNITY

In an effort to support the successes of both new and long-time members

of the ASH community, 2013 was a year of expanding education and

training opportunities at the Society. From the launch of the ASH Academy

eLearning platform to the release of the fifth edition of

ASH’s comprehensive Self-Assessment Program

(ASH-SAP) and exciting new opportunities for

aspiring hematologists to get involved, ASH

provided something for everyone, regardless

of years of experience in the field.


ASH® Academy2013 marked the launch of the ASH Academy, an interactive eLearning platform that provides quality improvement tools and education to hematologists at all stages of their careers. ASH members now have a single portal where they can assess and improve their medical knowledge, engage in quality improvement activities, and earn both Maintenance of Certification points and continuing medical education (CME) credits. ASH members can visit the ASH Academy to access educational products such as the ASH Self-Assessment

Program (ASH-SAP), complete practice improvement modules, and claim CME credit.

For more information visit www.ashacademy.org.

ASH Releases ASH-SAP, Fifth EditionIn June 2013 ASH released the fifth and most comprehensive edition of the ASH Self-Assessment Program (ASH-SAP). The ASH-SAP is an essential educational resource for hematologists and health-care professionals working in related fields to improve their practice methods and stay current with their professional education and certification requirements.

The fifth edition of ASH-SAP includes a review of both adult and pediatric hematology, including benign and malignant disorders, stem cell transplantation, laboratory hematology, and transfusion medicine. Three chapters new to this edition were developed as a direct result of feedback

received from ASH-SAP users and represent the Society’s efforts to meet the educational needs of its members and the broader hematology community.

From the ASH Academy site, users can access the online textbook, download a new eBook version, earn CME credit by taking the ASH-SAP exam, and, for an additional fee, access an ABIM-approved MOC module.

The ASH-SAP, Fifth Edition is also available in textbook form and contains a question-and-answer book that includes a self-assessment test with accompanying answers and annotations.

ASH Awarded Reaccreditation with Commendation from Accreditation Council for Continuing Medical EducationASH was resurveyed in 2013 by the Accreditation Council for Continuing Medical Education (ACCME) and awarded accreditation with commendation for six years as a provider of continuing medical education for physicians. The ACCME employs a rigorous, multilevel process

for evaluating institutions’ continuing medical education programs, according to the high accreditation standards adopted by all seven ACCME member organizations. More than 2,000 organizations have earned accreditation within the ACCME system.

Education & Training 232013 Annual Report

ASH Introduces New Membership Programs for Students, Residents, and FellowsTo further expand the ASH community, in 2013 the Society launched Fundamentals for Hematology Fellowship (FHF), a fellowship program-based approach to providing ASH benefits to hematology fellows. Fellows are enrolled in FHF by their training program and enjoy the following bundled benefits:

• ASH Associate membership, which includes complimentary subscriptions to Blood and The Hematologist, as well as discounts on ASH meetings and products

• One complimentary registration per academic year for one ASH meeting (ASH annual meeting, Highlights of ASH in North America, or State-of-the-Art Symposium)

• Online access for the full academic year to ASH Self-Assessment Program (ASH-SAP), Fifth Edition

In addition, recognizing the importance of all trainees to the ASH community, the Society added two new membership categories, one for medical and graduate students and the second for residents, to introduce potential future hematologists and hematology researchers to all that ASH has to offer. Members in each new category are now eligible to receive many of the regular benefits of ASH membership at no cost, including the online version of Blood, The Hematologist, and Hematology (the ASH Education Program) as well as reduced meeting registration fees.

For more information and to purchase visit www.hematology.org/ASHSAP.

Financial PictureASH continued to achieve solid financial standing in fiscal year 2013 as

in recent years. Operating revenues of approximately $45 million were

driven mainly by revenues from the annual meeting and Blood Journal.

Other sources of ASH revenue are derived from ASH’s small meetings

series, membership dues (only 10% of operating revenues), the ASH

Self-Assessment Program, and leased space from tenants in ASH’s

headquarters building.


With the increase in net revenue from programs, ASH was able to fund a multi-faceted effort to sustain critical blood disease research despite funding cuts to the National Institutes of Health (NIH) budget. The centerpiece of this effort, the ASH Bridge Grant program, commits $9 million over a three-year period to provide researchers with interim support to continue their hematology research that would otherwise not be funded due to sequestration and budget cuts.

As in previous years, during fiscal year 2013 (July 2012 – June 2013) ASH resources funded a variety of grants, awards, member benefits and other efforts: training programs, such as the Clinical Research Training Institute; global efforts, such as the Visitor Training

Program; advocacy efforts, such as members’ visits to advocate for hematology on Capitol Hill; and practice-related efforts, such as courses in consultative hematology. These and other expenditures totaled $40 million, allowing for a net income that is available to fund future years of the ASH Bridge Grant program.

Fiscal Year 2013 Audited Revenue Fiscal Year 2013 Audited Expenses

Annual Meeting

Blood Journal

Member Dues

Other

Program/Projects

Small Meetings

Operating Expenses

Programs/Projects

Blood Journal

Annual Meeting

Awards

Small Meetings

Facility

9% 12%

23%

20%

20%

12%

4%

To support the Society’s endeavors, visit www.hematology.org/Foundation.

47%

27%

10%

6% 5%

5%

252013 Annual Report

Contributions to ASHASH is extremely grateful for the generous contributions

noted below representing endowment gifts, grant

support, and individual contributions that helped to

further the Society’s mission in 2013.

Endowment GiftsWallace H. Coulter Foundation

• Grant Endowment Funding ($5 million)

• Wallace H. Coulter Award for Lifetime Achievement in Hematology

• Highlights of ASH® in Asia

• Highlights of ASH® in Latin America

• Clinical Research Training Institute in Latin America

• Outreach Initiatives in Mexico

• Global Hematology Association Leader’s Dinner

• ASH Travel Awards for Trainees from Developing Countries

ASH and the Wallace H. Coulter FoundationFor more than a decade, ASH’s collaboration with the Wallace H. Coulter Foundation (WHCF) has enabled the Society to extend its international reach and move closer to fulfilling its mission of conquering blood diseases worldwide. With the support and encouragement of the WHCF, ASH has launched bold initiatives, inspired global collaborations, and helped train a future generation of hematologists.

The ASH-WHCF partnership began in 2003 when the WHCF provided “seed” money to launch the ASH Clinical Research Training Institute. Since that time, ASH has expanded its education, training, and outreach initiatives to include the Translational Research Training in Hematology program in partnership with the European Hematology Association, the Highlights of ASH® program in Latin America and Asia, and the Clinical Research Training Institute in Latin America.

In addition, with the support of the WHCF, Mr. Coulter’s legacy lives on within ASH through the Wallace H. Coulter Award for Lifetime Achievement in Hematology. Mr. Coulter discovered the Coulter Principle – that electrical charge could be used to determine the size and number of particles in a solution. This discovery led to the Coulter Counter® and then flow cytometry, which revolutionized the practice of hematology and laboratory medicine. This award is the Society’s highest honor and recognizes an individual who has demonstrated a lasting commitment to the field of hematology through outstanding contributions to education, research, and practice.

In December 2013, the WHCF presented ASH with a generous $5 million endowment to commemorate the 100th anniversary of Wallace H. Coulter’s birth. The Foundation’s endowment will benefit the field of hematology for years to come and honor Mr. Coulter’s contributions to science and society, including his untiring efforts to help those whose quest for excellence was impeded by financial or geographic challenges.

The WHCF has given ASH the “risk capital” to think creatively, act globally, and support a new generation of hematology scientists and practitioners. The Society extends its sincere gratitude to the WHCF for its ongoing support.

Ernest Beutler Memorial Award Fund

• Ernest Beutler Lecture and Prize

Henry M. and Lillian Stratton Foundation

• Scholar Awards

Henry M. Stratton-Ernst R. Jaffé Scholarship Fund

• Scholar Awards

Joanne Levy, MD, Memorial Endowment Fund

• Joanne Levy, MD, Memorial Award for Outstanding Achievement

Mary Rodes Gibson Hemostasis-Thrombosis Foundation

• Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis

Sue Van, President of the Wallace H. Coulter Foundation, presents 2013 ASH President Janis L. Abkowitz, MD, with a check for $5 million at the 2013 ASH Annual Meeting. This endowment will provide funding to enable ASH to continue to develop innovative programs that continue Mr. Coulter’s legacy.


Individual ContributionsPlatinum Plus Circle ($10,000)

James N. George, MDEllen F. Levy

Platinum Circle ($2,500 - $9,999)

Janis L. Abkowitz, MDKaren Ballen, MDHal E. Broxmeyer, PhDLarry & Farrah CohenBarry S. Coller, MDHollyer Family & Keith

SchwartzAlan E. Lichtin, MDMartha Liggett, Esq.Mohandas Narla, DScBarbara Pro, MDMargaret V. Ragni, MD,

MPHThomas Roschak, MDRoy L. Silverstein, MDEileen Patricia Smith, MDThe Lifeblood Donor Advise

Charitable Fund - Thomas P. Stossel, MD

Martin S. Tallman, MDVan Brimer Family

FoundationGeorgia B. Vogelsang, MDJohn C. Winkelmann, MD

Gold Circle ($1,000 - $2,499)

Rafat Abonour, MD Ferdinand E.K. Addo, MD Barbara M. Alving, MD Kenneth C. Anderson, MD Nancy C. Andrews, MD,

PhD Thomas Bensinger, MD Nancy Berliner, MD Clara D. Bloomfield, MD Vassiliki A. Boussiotis, MD,

PhD Linda J. Burns, MD John C. Byrd, MD Morton Coleman, MD Charles Lee Conlon, MD Joseph M. Connors, MD Frank J. Daugherty, MD Michael R. DeBaun, MD Reed Drews, MD Tomas Ganz, MD, PhD

Matthew Gertzog, MBA, CAE

Leslie M. Howard, MD Robert A. Hromas, MD Kevin Imrie, MD Pamela M. Janco Marc J. Kahn, MD, MBA Anand Karnad, MD Suresh B. Katakkar, MD,

FRCPC Barbara A. Konkle, MD Richard A. Larson, MD Melissa K. Ledford, PA-C Stephanie J. Lee, MD, MPH Xavier Leleu, MD, PhD Jonathan D. Licht, MD Michael L. Linenberger, MD Jane Little, MD Marlene S. Violassi

Living Trust Madhu Mazumdar, PhD Joseph R. Mikhael, MD,

FRCPC, MEd Chevron Humankind

Matching Gift Program - Martha P. Mims, MD, PhD

Beverly S. Mitchell, MD Donna Neuberg, ScD Nonprofit HR Solutions Sarah O’Brien, MD Robert Z. Orlowski, MD,

PhD Dominique Piguet, MD Pierluigi Porcu, MD Charles T. Quinn, MD, MS Kanti R. Rai, MD Nishitha Reddy, MD William Reed, FASAE, CMP Robert M. Rifkin, MD Gerald J. Robbins, MD J. Evan Sadler, MD, PhD Kathleen Sakamoto, MD,

PhD Stanley L. Schrier, MD Margaret A. Shipp, MD Cancer Research &

Treatment Fund – Richard T. Silver, MD

Lawrence A. Solberg Jr., MD, PhD

Wendy Stock, MD Lillian Sung, MD, PhD Alexis Thompson, MD, MPH Michael Volk, MD, David J. Weatherall, MD Donna Weber, MD Andrew S. Weyrich, PhD David A. Williams, MD Jane N. Winter, MD

Silver Circle ($500 - $999)

Camille N. Abboud, MDGregory Abel, MD, MPHJohn W. Adamson, MDBurt Adelman, MDSteven L. Allen, MDMichael Auerbach, MDArthur W. Bracey Jr., MDThomas H. Carter, MD, PhDElaine Gayle Chottiner, MDCharles ClaytonH. Joachim Deeg, MDUlyana V. Desiderio, PhDPeter D. Emanuel, MDRobert E. Gallagher, MDArnold Ganser, MDNeil Goldenberg, MD, PhDJason Gotlib, MDJohn P. Greer, MDRobert I. Handin, MDStephen J. Harding, PhDDouglas K. Hawley, MDNancy Heddle, MScCharles Hesdorffer,

MBBCH, FCP(SA)John R. Hess, MDJeane Porter Hester, MDAnthony D. Ho, MD,

FRCPCStephen Hunger, MDMaen Hussein, MDTatsuo Ichinohe, MDInternational Consortium

On Acute Promyelocytic Leukemia – Manuscript Award

James Vincent Jordan Jr., MD

Judith Kleinerman, MDMichael H. Kroll, MDKeiki Kumano, MD, PhDMartha Lacy, MDLawrence L. Leung, MDKenneth G. Mann, PhDJeffrey Matous, MDKeith R. McCrae, MDJeffrey McCullough, MDMyo Min, MDAuayporn P. Nademanee,

MD, BSKathleen Neville, MD, MSAnna Niewiarowska, MDMichael O’Dwyer, MD,

FRCPathJulie A. Panepinto, MD,

MSPHThalia Papayannopoulou,

MD

Charles J. Parker, MDPeter Rintels, MDDaniel Rosenblum, MDAlan Glen Rosmarin, MDMervyn A. Sahud, MDDavid A. Scheinberg,

MD, PhDGary J. Schiller, MDCurtis L. Scribner, MDMilton W. Seiler Jr., MDEdward W. Soo, MDJohn J. Strouse, MD, PhDSylvia & Robert Scher

Charitable FoundationShigeki Takemoto, MDArthur A. Topilow, MDGeoffrey L. Uy, MD

Bronze Circle ($250 - $499)

Miguel R. Abboud, MDTiffany Ake, CPAJohn Anastasi, MDMurat O. Arcasoy, MDSteven Arkin, MDRichard H. Aster, MDJon C. Aster, MD, PhDGamal Badr, PhDHarriet A. Bering, MDNirmala Bhoopalam, MDChalmer & Anita BohlsMichael Boxer, MDLaurence A. Boxer, MDJames Bradner, MDAlan K. Burnett, MDC. Patrick Burns, MDThe Columbus Foundation –

Michael Caligiuri, MDNatalie Scott Callander, MDGregorio Campos-Cabrera,

MDVikki Ann Canfield, MDUsha Sree Chamarthy, MDConstellation Energy Group

Foundation, Inc.Seth J. Corey, MDChristine Margaret

Cserti-Gazdewich, BSc, MD, FRCPC

Lawrence Cytryn, MDLloyd E. Damon, MDYvonne Datta, MDSheldon J. Davidson, MDGeorgette Amantha

Dent, MDAnita Deshpande, MDAllen C. Eaves, MD,

FRCPC, PhD


Rebecca Elstrom, MDStephen G. Emerson, MD,

PhDMichael W. Evans, MD, MPHBruce L. Evatt, MDAli Fattaey, PhDMelissa Frei-Jones, MD, MSPatricia FrustaceSergio Giralt, MDScott D. Gitlin, MDTheodore Flint Gray III, MDNancy S. Green, MDDuPont Guerry IV, MDSunil Gupta, MBBS, FRCPCJulie Hambleton, MDJenifer HamiltonRalph F. Heaven Jr., MDPeiman Hematti, MDHelen E. Heslop, MDElizabeth Hexner, MD, MSCraig C. Hofmeister, MDJonathan Hoggatt, PhDAnne Hurlet-Jensen, MDElaine S. Jaffe, MDCage Saul Johnson, MDRonald Kerr, MDNeil Martin Kogut, MDPeter A. Kouides, MDAnn LaCasce, MD, MScLawrence S. Lamb Jr., PhDMarshall A. Lichtman, MDHwee Yong Lim, MDAlfredo R. Lopez, MDAlison Wakoff Loren, MD, MSTroy Lund, MD, PhDAlice D. Ma, MDPeter Martin, FRCPC, MD,

MSRodger McEver, MDEugene McPherson, MD, PhDAnna Rita Migliaccio, PhDTimothy Miley, MDMehdi M. Moezi, MDPaul Moorehead, MD, MS,

MScDavid Motto, MD, PhDCindy Neunert, MDMary Lynn R. Nierodzik, MDGayatri Nimmagadda, MDGrzegorz S. Nowakowski, MDJohn Peter Perentesis, MDCary PetersonLilli Petruzzelli, MD, PhDWillye B. Powell, MDTeresa Quiroga, MDMary Kathleen Reed, MD

Andrew W. Roberts, MBBS, PhD

Bongi A. Rudder, MBBSDaniel H. Ryan, MDRavindra Sarode, MDKo Sasaki, MD, PhDBipin N. Savani, MDAlvin H. Schmaier, MDSteven Spitalnik, MDRoberto Stasi, MD, PhDMargaret Clare Telfer, MDMichael A. Thompson, MD,

PhDRamon V. Tiu, MD, BSMasao Tomonaga, MD, PhDThomas Troeger, MDK. Gary J. Vanasse, MDGregory M. Vercellotti, MDSara K. Vesely, PhD, MPHLydia Villa-Komaroff, PhDAlberto Villalobos Prieto, MDNicholas Wickham, FRCPA,

FRACP, FRCPathMichael E. Williams, MDChristine S. Winter, MD,

FRCPTed Wun, MD, FACP, FRCPAIan Yudelman, MDIra Zackon, MDMichael Zakem, DOLeonard I. Zon, MD

Friends Circle (up to $249)

Sophia Adamia, PhDKenneth Adler, MDJose Carlos Aguilar Luna Sr.,

MDMichael S. AllenAli Al-Shanqeeti, MDMammo Amare, MDBabara AmeerAchilles Anagnostopoulos, MDElizabeth Anderson, PhDAnonymousJennifer AntonacciFernando Luiz Vieira

De Araujo Sr., MDFernando A.M. Claret

Arcadipane, PhDRaul F. Arce Levi, MDMartha Arellano, MDMichael Attoh, MDJames P. Aubuchon, MDBanu Aygun, MDPatricio Azaola, MDGrover C. Bagby Jr., MD

Poonkuzhali Balasubramanian, MSc, PhD

Phillip E. Baldwin, MDEmily Elizabeth Bart-Smith,

MRCP, BScPeter Batar, MD, PhDSubhose Bathina, MDPia Baumann, MD, PhDLarry Beck, MDPamela S. Becker, MD, PhDRita Bellevue, MDLennette J. Benjamin, MDJoel S. Bennett, MDChristopher B. Benton, MDVasilios Berdoukas, MBBSJeffrey L. Berenberg, MDWolfgang Bergmeier, PhDSita D. Bhella, MDJames J. Bieker, PhDHenny Heisler Billett, MDMichael R. Bishop, MDAmy Blithe, BSc,Gerd Blobel, MD, PhDEric Block, PhDDavid M. Bodine, PhDLawrence H. Boise, PhDNicolas Bonadies, MDChallice L. Bonifant, MD, PhDUma Borate, MDMarija Borosak, FRCPA,

FRACP, MBBSErica Boswell, BSMarek J. Bozdech, MDJames E. Bradner, MDDanielle M. Brander, MDEmery Bresnick, PhDBrett Thomas Brinker, MD, MSRobert BroadnaxWolfgang Brockhaus, MDLuiz A. Bruno, MDChris Y. Brunson, MDMark W. Brunvand, MDLocke J. Bryan, MDPaulette Bryant, MDWanda Buchheit, PA-CEdwarda M. Buda, MDUlrich Budde, MDGuntram Buesche, MDSusan BuhrowJohn H. Bushweller, PhDAndrew A. Butler, PhDHubertus C. Buyck, MBChBChristian Thomas Cable, MDAndrew D. Campbell, MDRicardo Carter, MDJanuario Castro, MD

Carla Casulo, MDSpero Cataland, MDRose Catchatourian, MDDaniel Catovsky, MD, FRCPThomas Caughey, MDRonjon Chakraverty, BMBS,

PhDKai ChanVictor T. Chang, MDSamuel Charache, MDJoel Anne Chasis, MDJulio C. Chavez, MDLinzhao Cheng, PhDWichai Chinratanalab, MDNicholas Chiorazzi, MDJonathan Cho, MDMi Rim Choi, MDTimothy P. Clackson, PhDE. Leila Jerome Clay, MDJacqueline Cloos, CAE, PhDAlan R. Cohen, MDJohn T. Cole, MDNathan Theodore Connell, MDRachel Cook, MS, MDSarah Cooley, MD, MSJohn V. Cox, DO, MBALuke Coyle, MBBSPamela Ann Crilley, DOJohn Crispino, PhD, MBAAdam Cuker, MD, MSDavid Spencer Currle, PhDMary Cushman, MD, MScCustomInkJanet Cuttner, MDParastoo Bahrami Dahi, MDAlexey V. Danilov, MDDeepika S. Darbari, MDMatthew S. Davids, MDPeter Wright Davis, BAJill de Jong, MD, PhDManuel De La Puerta, MDBas De Laat, MD, PhDMaria de la Fuente de Villa,

MDLinda C. Demarco, MDChangchun Deng, MD, PhDJohan A. Dierick, MDDistrict Hospital Partners, L.P.Carlos J. Dominguez, MDAndrew Dorr, MDJoseph J. Dudek, MDM. DuinTamara J. Dunn, MDHien K. Duong, MDJanice P. Dutcher, MDMary Eapen, MBBS, MS


Dimitar Efremov, MD, PhDLaurence Elias, MDSherine F. Elsawa, PhDZoran Erjavec, MDSusan Escudier, MDGerman A. Espino, MDAugusto B. Federici, MDSteven Fein, MD, MPHDonald I. Feinstein, MDYuxin Feng, PhDLouis Flamand, PhD, MBABarry Flannelly, PharmDCatherine A. Flynn, BAPaula Fraenkel, MDWilliam Eric FrangeJames French II, MDJonathan Friedberg, MDEllen W. Friedman, MDElke K. Friedman, MDLynn FrohnmayerFred FulloRenee E. Funches, MDPeter R. Galbraith, MD,

FRCPCKate Gardner, MA, MRCP,

MBBSLina Maria Gaviria Jaramillo,

MDMartine George, MDAaron T. Gerds, MD, MSStanton L. Gerson, MDSaghi Ghaffari, MD, PhDRajendra Gharbaran, PhDIrene Ghobrial, MDLaus Gianluca, MDHeidi H. Gillenwater, MDAntonio Giulivi, MDMark A. Goldberg, MDStuart Goldberg, MD

Edward D. Gomperts, MDKathleen Goss, PhDJoachim Rudolf Göthert, MDAkihiko Gotoh, MDJennifer K. Goy, MD, MScNadine Ghislaine GradelBlazenka Grahovac, PhDJames M. Granfortuna, MDJochen GrassingerRalph Green, MD, PhDJames D. Griffin, MDGeorge Grigoriadis, MBBS,

PhD, BScStephan A. Grupp, MD, PhDAndreas Gschwend, MDElizabeth Guevara, MDCindy HaaseEric Hailman, MD, PhDRonald D. Halvorson, MDAyad Hamdan, MDBetty K. Hamilton, MDDale E. Hammerschmidt,

MD, FACPNancy M. Hardy, MDMichael B. Harris, MDHisayoshi HashimotoKathryn Hassell, MDKiyohiko Hatake, MD, PhDShilpa M. Hattangadi, MDSabine Irene HeineJohn A. Heit, MDCharles S. Hemenway, MD,

PhDJeanne Hendrickson, MDJose Mario Hernandez

Rodriguez Sr., MDSteven Herring, PhD, BSTomohiro Hirade, MDGerald HirnDoris HirschhornGabriela Hobbs, MDNina HoffmanTerzah M. Horton, MD, PhDLori HorvatDianna Howard, MDHui Huang, PhDYu-Chung HuangDavid Huebner-Chan, MDRafael Hurtado Monroy, MDShafkat Hussain, MDJessica HussellGretchen Ibele, MDTadahiko Igarashi, MD, PhDAnwar M. Iqbal, PhDTadao Ishida, MD, PhD

Eiichi Ishii, MD, PhDCassandra L. JacobsChristian Jakob, MD, PhDRobyn Javier, PhDOluyemi M. Jeje, MBBSDavid E. Jenkins Jr., MDKyle A. Jensen, PhD, MSPeng Ji, MD, PhDItsuro JinnaiGretchen Johns, MDJill Johnsen, MDBonny L. Johnson, MSNNuruddin Jooma, MD, MPHDavid Kandel, MDRobert C. Kane, MDYuanxi Kang, PhDJulie Kanter, MDSilke Kapp-Schwoerer, MDHazhar Karim, MD, PhDMargaret Kasner, MDGregory J. Kato, MDDan S. Kaufman, MD, PhDRika KawasakiSabine Kayser, MDAnn Kelley, MDPamela H. Kempert, MDWilliam Kern III, MDNancy A. Kernan, MDMoon Hwan Kim, PhDFumihiko Kimura, MDMichael G. KingCarrie Kitko, MDLeonard M. Klein, MDPeter Klein, MBAOrly Klein, MD, BAElizabeth Klings, MDMary Ann Knovich, MDStefan Koehrer, MDAimee Kohn, MD, PhDBoon Cheng Kok, MDHans-Jochem Kolb, MDYukio Kondo, MDMarcel Koopman, PhDGoldi A. Kozloski, PhDJennifer Krajewski, MDDiane Krause, MD, PhDJonathan S. Krauss, MDOleg I. Krijanovski, MD, PhDRebecca Kruse-Jarres, MD,

MPHAshish Arun Kshatriya,

BPharm, MScDe-Hui Ku, PhDNicole Kucine, MD

Carolina Kuipers, MScHidemitsu Kurosawa, MDManabu Kusakabe, MD,

PhDMeir Lahav, MDMarc Lalancette, MD, FRCPMy Thi Lam, PhDThomas A. Lane, MDAmelia Langston, MDSophie Lanzkron, MDRoberto LaraAlejandro Lazo-Langner,

MD, MScTucker W. LeBien, PhDDean Anthony Lee, MD,

PhDChristopher Charles

Lemasters, MBALance Leopold, MDSuzanne M. Leous, MPANorma Lerner, MD, MPHPaul Liberti, PhDJane L. Liesveld, MDCaroline Ariane Lindemans,

MD, PhDMark R. Litzow, MDPaul Pu Liu, MD, PhDJerome M. Loew, MDThomas Ward Loew, MDRichard Lottenberg, MDSean R. Lynch, MDChun Kei Kris MaGrace Macaulay, MDJamie L. Maciaszek, BS, MSB. Gail Macik, MDAnthony J. Magdalinski, DOMattias Magnusson, PhDSami Malek, MDRam Mandalam, PhDHilda M. Mangos, MBChBRolf-Reinhard Marell, PhDMichael J. Maresca, MDRichard Marks, MSBeth Ann Martin, MDGenoveva Martinez-

Poventud, MDDai Maruyama, MD, PhDRiccardo Masetti, MDAisha Masood, MDVikram Mathews, MDBlanche Mavromatis, MDDebra L. Mayo, PharmDAmitabha Mazumder, MDPhilip L. McCarthy, MDTimothy McCavit, MD


Robert McCroskey, MDLisa McGarryCatherine E. McGuinn, MDShannon McKinney-Freeman,

PhDGordon D. McLaren, MDPeter McPhedran, MDRobert T. Means Jr., MDEmily Meier, MD, FAAPThomas Melchardt, MDAnthony A. Meluch, MDManoj P. Menon, MDLinda S. MercerGiampaolo Merlini, MDSara E. Meyer, PhDKenichi Miharada, PhDCarole B. Miller, MDAlice S. Mims, MDAlexander C. Minella, MDCatherine J. Moltzan, MD,

FRCPCAmelie C. Montel-Hagen, PhDMichael MontgomeryMabast MoohialdinJoseph O. Moore, MDRoksana MoraghebiCharles Q. Morris, MBChB,

MRCPTammy Morrish, PhDElaine A. Muchmore, MDKaren Norman MuellerCharles Mullighan, MBBS,

FRACP, MD, FRCPA, MScAnant MurthyRickey Myhand, MDKevin A. Nacho-Vargas, MDPhilipp Daniel NagelSuparna Nanua, MD, PhDAnupama Narla, MDJuana Ines Navarrete, MDAsha Nayak, MDMarshall NayerThomas Neal Jr., MDPeter E. Newburger, MDDebra K. Newman, PhDPeter J. Newman, PhDVu N. Ngo, PhDShunbin Ning, PhDDavid S. Nix, MDStephen J. Noga, MD, PhDEnrico M. Novelli, MDUlrike Nowak-Goettl, MDConor John O’DonovanSolomon Fiifi Ofori-Acquah,

PhDMohammed Ogaily, MD

Daisuke Okamura, MDUjunwa Cynthia Okoye-

Okafor, MSHeather A. O’Leary, PhDMoacyr R. Oliveira, MDArsinur Oral, MDTimothy J. O’Rourke, MDEdward O’Rourke, MSMotomi Osato, MD, PhDChristopher J. Ott, PhDBabatunde O. Oyajobi,

MBBS, PhD, MBASwaminathan Padmanabhan

Iyer, MDIlaria Stefania Pagani, PhDEduardo R. Pajon, MDEleftherios Papoutsakis, PhDRonald Paquette, MDBarry H. Paw, MD, PhDMary-Elizabeth M. Percival,

MDJaime Pereira, MDRita Perlingeiro, PhDMichael E. Petrone, MD, MPHEfthimios Petroutsas, RPhMary Philip, MD, PhDJohn Phillips, PhDPeter V. Pickens, MDAndrew S. Pierson, MDSandra & Harvey PikoffKimberly K. PluennekeDaniel Aaron Pollyea, MD, MSVit ProchazkaAmanda H. PrusVijayalakshmi Puram, MDIan Quirt, MDVivek S Radhakrishnan, MD,

DM, MScElizabeth Raetz, MDLakshmi Ramadurai, PhDReshma Ramlal, MDVirginia RamseySaeeda RanaBruce G. Raphael, MDAaron P. Rapoport, MDYaddanapudi Ravindranath,

MBBSEugene Price Reese Jr., MDErin G. Reid, MD, MSClarice Reid, MDRobert Edwin Reid IILorenz Risch, MD, MPHPatricia D. Risse, PharmDEllen Ritchie, MDStefano Rivella, PhDGustavo A. Rivero, MD

David A. Rizzieri, MDGail J. Roboz, MDJose Rodriguez-Carrillo, MDGinger Rogers, MDLinda M. RogersJames S. Roloff, MDRizwan Romee, MDCatherine C. Rosales, MDSteffen Rosen, PhDDavid S. Rosenthal, MDCindy N. Roy, PhDJames Rubenstein, MD, PhDBruce Sachais, MD, PhDAniket Saha, MD, MSKasim Abdul Salim, MD,

FRCPSergio Sanchez-Guerrero, MDEric Sandler, MDKristen M. Sanfilippo, MDChitta Sarker, MDSarah E. Sartain, MDKen Sato, MD, PhDWilliam Savage, MD, PhDNobukuni Sawai, MD, PhDKirk SchampElaine Schattner, MD, MARobert Schaub, PhDGeraldine P. Schechter, MDAaron Schimmer, MD, PhDReinhard Schneppenheim,

MD, PhDHarry C. Schouten, MDFriedrich Schuening, MDMary-Frances Scully, MRCPJonathan Serody, MDPaul Jean Shami, MDJessica Carolyn Shand, MDDana Shani, MDRichard J. Shearer, MDJohn P. Sheehan Jr., MDVincent S. Shen, MDShalini Shenoy, MDPatricia A. Shi, MDMunetake ShimabeRyosuke Shirasaki, MDStephen B. Shohet, MDDeborah M. Siegal, MD, MScJeffrey M. Silberberg, MDAlex Pimenta Silva, MDJitsuda Sitthi-Amorn, MDKavitha Siva, PhDEvan D. Slater, MDArne Slungaard, MDMitchell R. Smith, MD, PhDDavid S. Snyder, MDMartha Sola-Visner, MD

Natthapol Songdej, MD, MPHScott Sonnier, MDSoutheast Florida Hematology

Oncology GroupCarol SpearJohn D. Sprandio Jr., MDKrishnan Srinivasan, MDSondra SteckerCindy Steele, MDBarbara Anne & Kenneth

StephensJan Storek, MD, PhDMarion S. Subklewe, MDJaya SubramaniamChris Sugg, PharmDKenneth Sumida, MDNancy Sun, MDKenshi Suzuki, MD, PhDRonald Swaab, MDYasunobu TakeokaTakeshi Taketani, MDMark Tanner, BScCatherine Regina Taylor,

PharmDJames G. Taylor, MDElisa Ten HackenNabil Thalji, BSRaymond Thertulien, MD, PhDBrian G. Till, MDNaoto Tomita, MD, PhDBryan J. Trottier Jr., MDAnna G. Trudgett, MA, ELSDonald Edward Tsai, MD, PhDRobert Ralph TurnerRyosuke Ueda, MDLynne Uhl, MDMatthew L. Ulrickson, MDNoriko Usui, MDPraveen Vashist, MDBenjamin Vincent, MDMaria A. Vinogradova, MDMartin VogelPhyllis VogelNicolas von der Weid, MDEvan Vosburgh, MDJohn WagnerThomas A. Waldmann, MDDonna A. Wall, MDJames G. Wall, MDKatherine J. Walsh, MDWilliam Vincent Walsh, MDAnnette Olga Walter, PhDPatrick B. Walter, MSc, PhDFarooq Ahmad Wandroo, MD,

FRCPath, FRCPY. Lynn Wang, MD, PhD


Jing H. Wang, MD, PhDZhao Wang, MD, PhDReina Watanabe, MDPaul Frederick Weber, MD,

RPh, MBAAlissa A. Weber, MDNeal J. Weinreb, MDKatja WeiselLukas Weiss, MDKarl Welte, MDRandal Joseph Westrick, PhDV. Michael Whitehead, MDMichele WhitehillJames A. Whitlock, MDBrian M. Wicklund, MDCM,

MPHPeter H. Wiernik, MDBrent A. Williams, MDChristopher Kwesi Williams,

MD, FRCPCAlan Cecil Wine, MDBirte Wistinghausen, MDDon M. Wojchowski, PhDIda Wong-Sefidan, MDElizabeth WoodsGerald Milton Woods, MDJ. Fraser Wright, PhDCatherine T. Yan, PhDDongqing Yan, PhDJoanna S. Yi, MDWang Ying, MDJeongsook YoonLily M. Young, MDStephanie Young, PharmDDaniele Zama, MDYanming Zhang, MDEric Zhao, PharmDMarc Zumberg, MD

Tribute GiftsIn honor of Janis Abkowitz, MDTomas Ganz, MD, PhDMichael L. Linenberger, MDIn honor of Charles Abrams, MDRachel Cook, MS, MDIn honor of Emmett Broxson, MDJames French II, MDIn honor of John C. Byrd, MDNishitha Reddy, MDIn honor of Michael DeBaun, MDPatricia Frustace In honor of Kenneth Kaushansky, MDRobert A. Hromas, MDIn honor of Marshall Lichtman, MDRalph Green, MD, PhD

In honor of Rajul B. ParikhPraveen Vashist, MDIn honor of Dr. Kouichi R. TanakaDonald Paglia, MDIn honor of Marilyn Telen, MDPatricia Frustace In honor of William N. Valentine, MDDonald Paglia, MDIn honor of Ralph WalkrsteinMervyn A. Sahud, MDIn honor of Sidney Whiteheart, MDSusan Buhrow

Memorial GiftsIn memory of Dr. Karl BlumeBeverly S. Mitchell, MD Eileen Patricia Smith, MD In memory of Mary Vance McClelland BohlsChalmer & Anita BohlsKaren Norman MuellerLinda M. Rogers Barbara Anne & Kenneth StephensIn memory of Dr. Mark S. BrowerElaine Schattner, MD, MA In memory of Jack B. BuchheitWanda Buchheit, PA-CIn memory of Norma Jean BurnsJane Little, MDIn memory of John CarewCarol SpearIn memory of Dr. Lup Yiu ChanRobert Ralph TurnerIn memory of Dr. Jon DeloreyElizabeth Woods In memory of Dr. and Mrs. DuPont Guerry, IIIDuPont Guerry IV, MDIn memory of Warren Candler HarrisAmanda H. Prus

In memory of Vivian HeinzCindy HaaseIn memory of Dr. Mina IzadyarPeiman Hematti, MDIn memory of Dr. Robert JancoPamela M. Janco In memory of Mrs. Sunila KatakkarSuresh B. Katakkar, MD, FRCPCIn memory of Ann MuldorfDoris HirschhornPhyllis VogelIn memory of Sheri Lynn Clark MyersLawrence S. Lamb Jr., PhDIn memory of Samuel RappaportStanley L. Schrier, MD In memory of Robert SchollKatherine J. Walsh, MDIn memory of Sonny and NanaBryan J. Trottier Jr., MDIn memory of Georgieann SquirosThomas Roschak, MDIn memory of Dr. Jane C. WeeksGregory Abel, MD, MPH In memory of Vicki Martof WiltAlan E. Lichtin, MD


Corporate FriendsASH appreciates the relationships that are maintained with our Corporate Friends, which

represent a valuable opportunity to further the understanding of critical issues facing the

hematology community.

ONCOLOGY

ONCOLOGY

Farbe/colour:PANTONE 288 CV

Corporate SupportASH sincerely appreciates the support received from the corporate community, which helped

fund critical Society initiatives such as the Society’s award programs, annual meeting, State-of-

the-Art Symposia, and Highlights of ASH meetings. ASH would especially like to acknowledge

the leading supporters of our initiatives and programs in 2013:

ASH Member BenefitsWhether a clinician or a researcher, a senior academician or a fellow in training,

hematologists at every career level will find that ASH has much to offer. The following

benefits are offered exclusively to Society members*:

Subscriptions• Blood, the official journal of the

American Society of Hematology and most-cited peer-reviewed publication in the field

• Access to the Blood journal mobile app for iOS, Android, and Blackberry smartphones and tablet computers

• Hematology (the ASH Education Program), a comprehensive clinical update published in conjunction with the annual meeting

• The Hematologist, the Society’s award-winning bimonthly newsletter

• ASH NewsLink, a monthly electronic newsletter

Special Privileges• Access to early-bird annual

meeting registration and priority members-only hotels before annual meeting registration and housing opens to the general public

• Eligibility to submit or sponsor abstracts

• Ability to apply for ASH awards and grants, including ASH Bridge Grants

• Eligibility to hold office and serve on committees

• Ability to discuss difficult patient cases with renowned hematologists through ASH’s Consult-a-Colleague program

• Access to ASH’s online member directory

• Eligibility to be listed in ASH’s patient-accessible database, Find a Hematologist

• Access to the “ASH Club” and fitness center at ASH Headquarters located in Washington, DC

Discounts• More than $400 in discounts

on annual meeting registration

• Deep discounts on registrations for the Society’s smaller Highlights of ASH meetings and State-of-the-Art Symposia

• Discount on the new fifth edition of ASH Self-Assessment Program (ASH-SAP)

• Reduced rates on ASH meeting webcasts and other educational products

*Note: The benefits listed above are for full (Active and International) members. Complimentary membership is available to students and residents with benefits that include online access to Blood, The Hematologist, and Hematology (the Education Program) as well as reduced meeting registration fees.


American Society of Hematology

2021 L Street NW, Suite 900

Washington, DC 20036

Phone: 202-776-0544

Email: [email protected]

Website: www.hematology.org

www.twitter.com/ASH_Hematology

www.facebook.com/AmericanSocietyofHematology

2013 Annual Report - Amazon S3 · of an important initiative that aims to ensure that ASH’s...

Documents

Transcript of 2013 Annual Report - Amazon S3 · of an important initiative that aims to ensure that ASH’s...